Symphogen A/S Presents New pan-HER data at Annual American Association for Cancer Research Meeting
Symphogen today at the Annual Meeting of the American Association for Cancer Research in Washington DC, presented new preclinical data suggesting that a mixture of antibodies, known as pan-HER, that simultaneously inhibits EGFR, HER2 and HER3, is superior to existing targeted therapies in dealing with both primary and acquired resistance due to HER family dependency.